Literature DB >> 15727243

Accuracy of cancer family histories: comparison of two breast cancer syndromes.

Katherine A Schneider1, Lisa M DiGianni, Andrea Farkas Patenaude, Neil Klar, Jill E Stopfer, Kathleen A Calzone, Frederick P Li, Barbara L Weber, Judy E Garber.   

Abstract

Cancer risk programs rely on accurately reported family history information. This study compares the accuracy with which cancer sites and ages at diagnosis are reported by Li-Fraumeni syndrome (LFS) and hereditary breast-ovarian cancer syndrome (HBOCS) families undergoing genetic testing. We analyzed the accuracy of 191 cancer diagnoses among first-degree (FDRs) and second-degree (SDRs) relatives reported by 32 LFS and 52 HBOCS participants in genetic testing programs. Cancer diagnoses of relatives were more accurately reported in the HBOCS cohort (78%) than in the LFS cohort (52%). Almost all breast cancer diagnoses were accurately reported, whereas 74% of ovarian cancer diagnoses and only 55% of other LFS-related cancers were accurately reported. Age at diagnosis was accurate within 5 years for 60% of LFS relatives and 53% of HBOCS relatives. Factors correlating with accurate reporting of cancer history included: being member of BRCA1 family, higher education level, female historian, degree of closeness to affected relative, and having fewer than 5 affected FDRs and SDRs. Relying on verbal histories would not have altered eligibility for genetic testing among HBOCS historians, but fewer than half of LFS historians provided information that would have led to TP53 testing. Our data suggest that it may not be necessary to confirm breast cancer diagnoses routinely; however, documentation of other cancer types remains important for appropriate risk assessment and follow-up.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15727243     DOI: 10.1089/gte.2004.8.222

Source DB:  PubMed          Journal:  Genet Test        ISSN: 1090-6576


  14 in total

1.  No evidence of excess breast cancer risk among mutation-negative women from BRCA mutation-positive families.

Authors:  Larissa A Korde; Christine M Mueller; Jennifer T Loud; Jeffery P Struewing; Kathy Nichols; Mark H Greene; Phuong L Mai
Journal:  Breast Cancer Res Treat       Date:  2010-05-11       Impact factor: 4.872

2.  Eligibility for magnetic resonance imaging screening in the United Kingdom: effect of strict selection criteria and anonymous DNA testing on breast cancer incidence in the MARIBS Study.

Authors:  D Gareth R Evans; Fiona Lennard; Linda J Pointon; Susan J Ramus; Simon A Gayther; Nayanta Sodha; Gek E Kwan-Lim; Martin O Leach; Ruth Warren; Deborah Thompson; Douglas F Easton; Rosalind Eeles
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-06-30       Impact factor: 4.254

3.  Considerations for the impact of personal genome information: a study of genomic profiling among genetics and genomics professionals.

Authors:  Julianne M O'Daniel; Susanne B Haga; Huntington F Willard
Journal:  J Genet Couns       Date:  2010-03-30       Impact factor: 2.537

4.  THE GORDON WILSON LECTURE EVOLUTION OF CLINICAL CANCER GENETICS.

Authors:  Judy E Garber
Journal:  Trans Am Clin Climatol Assoc       Date:  2016

5.  American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers.

Authors:  Karen H Lu; Marie E Wood; Molly Daniels; Cathy Burke; James Ford; Noah D Kauff; Wendy Kohlmann; Noralane M Lindor; Therese M Mulvey; Linda Robinson; Wendy S Rubinstein; Elena M Stoffel; Carrie Snyder; Sapna Syngal; Janette K Merrill; Dana Swartzberg Wollins; Kevin S Hughes
Journal:  J Clin Oncol       Date:  2014-02-03       Impact factor: 44.544

6.  Completeness of pedigree and family cancer history for ovarian cancer patients.

Authors:  Yedong Son; Myong Cheol Lim; Sang Soo Seo; Sokbom Kang; Sang Yoon Park
Journal:  J Gynecol Oncol       Date:  2014-08-05       Impact factor: 4.401

7.  Cancer Incidence in First- and Second-Degree Relatives of BRCA1 and BRCA2 Mutation Carriers.

Authors:  Haley Streff; Jessica Profato; Yuanqing Ye; Denise Nebgen; Susan K Peterson; Claire Singletary; Banu K Arun; Jennifer K Litton
Journal:  Oncologist       Date:  2016-06-15

8.  Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors.

Authors:  Bronson D Riley; Julie O Culver; Cécile Skrzynia; Leigha A Senter; June A Peters; Josephine W Costalas; Faith Callif-Daley; Sherry C Grumet; Katherine S Hunt; Rebecca S Nagy; Wendy C McKinnon; Nancie M Petrucelli; Robin L Bennett; Angela M Trepanier
Journal:  J Genet Couns       Date:  2011-12-02       Impact factor: 2.537

9.  Low accuracy of self-reported family history of melanoma in high-risk patients.

Authors:  Nicholas D Flint; Michael D Bishop; Tristan C Smart; Jennifer L Strunck; Kenneth M Boucher; Douglas Grossman; Aaron M Secrest
Journal:  Fam Cancer       Date:  2021-01       Impact factor: 2.375

10.  Prevalence of germline TP53 mutations in HER2+ breast cancer patients.

Authors:  Michelle G Rath; Serena Masciari; Rebecca Gelman; Alexander Miron; Penelope Miron; Kathleen Foley; Andrea L Richardson; Ian E Krop; Sigitas J Verselis; Deborah A Dillon; Judy E Garber
Journal:  Breast Cancer Res Treat       Date:  2013-04-12       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.